Exact Sciences Corp
EXAS: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$54.00 | Qyyq | Xdgcxkr |
Exact Sciences Earnings: Cologuard Continues to Grow at Strong Pace and Shares Undervalued
Exact Sciences delivered excellent third-quarter results on Cologuard expansion. Guidance for 2023 was raised again, with midpoint guidance for total revenue now at $2.481 billion, or $25 million higher than previous guidance, and screening revenue now at $1.85 billion. We maintain our fair value estimate of $78 per share. The shares are trading at a 17% discount to our fair value, which we view as modestly undervalued.